Dan Teleman
Chief Executive Officer Nasus Pharma
Seminars
Thursday 21st May 2026
Exploring Powder-Based Intranasal Delivery as a Platform for Systemic Therapeutics
2:30 pm
- Compare powder versus liquid intranasal delivery, highlighting how deeper nasal deposition, increased surface area, and richer vascular access can drive faster and higher systemic absorption
- Explore the critical challenges of particle size distribution, particle shape, and limited large-scale manufacturing capacity, and how proprietary formulation strategies can address them
- Advancing powder-based naloxone and epinephrine programs, including device considerations, scalability planning, and where innovation is still needed across delivery technologies and manufacturing infrastructure
